Interleukin Genetics, Inc.

Other

Sitokine Limited

Cardioforecast Ltd.

Medical Science Systems, Inc.

Warner-lambert Company

Entelos, Inc.

Orig3n, Inc.

Kenneth S Kornman

Gordon W Duff

Lynn Doucette-Stamm

David C Crossman

Sheila E Francis

Pamela K Fink

Simon Van Dijk

Kenneth M Huttner

John Rogus

Katherine Stephenson

Thomas S Paterson

Debra J Moore

Samuel Holtzman

Katherine Martinez

Christopher J Moehle

Xiaodong Wu

Paul Martha

L Tandy Herren

Ivan T Myers

Hwa-Ying Wang

Joseph D Clark, Jr

Stanley C Holt

Paul M Martha, Jr

Steven Offenbacher

Kenneth Huttner

Leon Wilkins

Hong Min Chen

The present invention relates to methods and kits for treating cardiovascular disease.

Methods and kits for treating cardiovascular disease

The present invention provides stratification methods and kits to identify whether an individual having an inflammation-related disorder has genotype-specific differential expression of IL-1, i.e., is a 'high' or 'low' producer of IL-1, such that s/he can be provided an appropriate anti-inflammatory drug and at an appropriate dose. The stratification of high or low IL-1 producers is used to guide assignment of different drug doses and therefore reduce drug toxicity and adverse events in an individual who, without stratification, may be prescribed a higher dose than needed to manage the primary indication. The use of IL-1 stratification of drug dosing would allow a better clinical benefit-risk appraisal in an individual patient.

Methods for predicting response to treatment

The present invention relates, in part, to methods and kits for treating cardiovascular disease.

An improved method and kit of determining whether a patient is predisposed to having severe periodontal disease and/or having high risk of progression of periodontal disease, comprising the steps of (i) taking a biological sample from said patient; (ii) genotyping said biological sample for genetic polymorphism pattern comprising IL 1B (rs16944), IL 1B (rs1143623) and IL 1B (rs4848306); and (iii) comparing said genetic polymorphism patterns to a reference composite genotype pattern; wherein the similarity of said genetic polymorphism patterns to said reference pattern indicate said patient's predisposition to having severe periodontal disease and/or having high risk of progression of periodontal disease.

Method for determining severity and progression of periodontal disease

The invention provides methods and compositions relating to identification and use of genetic information from the IL-I gene cluster&#x2014;including the structure and organization of novel IL-I-like genes found within the IL-I locus as well as polymorphisms and associated haplotypes within these genes. The invention thereby expands the repertoire of useful genetic information available from the IL-I locus&#x2014;which contains the previously-identified IL-1&#x3b1;, EL-1&#x3b2; and IL-IRN genes, for predicting IL-I associated phenotypes (e.g. increased or decreased risks of inflammatory disease) and for treating IL-I haplotype associated inflammatory phenotypes.

IL-1 gene cluster and associated inflammatory polymorphisms and haplotypes

The invention provides methods and compositions relating to identification and use of genetic information from the IL-1 gene cluster&#x2014;including the structure and organization of novel IL-1-like genes found within the IL-1 locus as well as polymorphisms and associated haplotypes within these genes. The invention thereby expands the repertoire of useful genetic information available from the IL-1 locus&#x2014;which contains the previously-identified IL-1&#x3b1;, IL-1&#x3b2; and IL-1RN genes, for predicting IL-1 associated phenotypes (e.g. increased or decreased risks of insulin resistance associated pathologies) and for treating IL-1 haplotype associated insulin resistance associated pathologies.

IL-1 gene cluster, insulin resistance and coronary artery disease associated polymorphisms and haplotypes and methods of using same

The kits and methods of the present invention relate to the diagnosis of cardiovascular disorders. In one aspect, the invention discloses a method and a kit for determining whether a subject has a fragile plaque disorder. In one aspect, the invention discloses a method and a kit for determining whether the subject has an occlusive disorder. In one aspect, the invention discloses a method and a kit for determining whether the subject has a restenosis disorder. Other methods of the present invention relate to the selection of therapeutics for a patient with a cardiovascular disease.

Method for diagnosing myocardial infarction

Diagnostics and therapeutics for osteoporosis, which are bases upon the identification of a subjects IL-1 haplotype and genotype pattern are described.

Diagnostics and therapeutics for osteoporosis

Methods, assays and kits are disclosed for detecting a mother's or a fetus's susceptibility to an adverse pregnancy outcome such as low birth weight. The methods comprise obtaining a biological sample from a patient and determining the presence or absence of an IL-1 allele 2 of a marker that is associated with an adverse pregnancy outcome.

Fetal testing for prediction of low birth weight

A method of predicting whether a subject is predisposed to developing early-onset menopause is provided. The method involves genotyping a patient at the IL-1 gene loci.

Methods of diagnosing early-onset menopause

Methods and kits for determining whether a subject has or is predisposed to developing restenosis are provide.

Diagnostics and therapeutics for restenosis

Diagnostics for cardiovascular disorders

A system including a set of software based Explorers, and a computer assisted methodology support the development of new medical interventions for diseases. The system includes Explorer modules for discovering proposed interventions, designing clinical trials, performing pharmacoeconomic analysis, and illustrating disease progression for various patients over time including creating disease progression tutorials for patients. The Explorers support a bottom-up or data driven methodology that enables a user, such as medical researcher, to mine data sources of clinical, biologic, expert or other types of data to discover, test, evaluate, and understand a proposed intervention and its impact on disease progression in different patient types. A Target Discovery Explorer assists the user in identifying leverage points in disease progression in relationship to various patient attributes and interventions, thereby identifying a proposed intervention for the desease. A Clinical Trials Explorer assists the user in designing clinical trials based through identification of combinations of patient attributes and intervention attributes that yield efficacious changes in selected disease progression measures. A Pharmacoeconomic Explorer enables the user to determine relative costs-benefits of a proposed intervention for patients, practitioners, and payers, including quality of life results for patients, practice results for practitioners, and financial payment results for payers. A Disease Progression Explorer enables the user to visually project disease progression for specified patient attributes and interventions, in order to better understand and explain the effects of an intervention on a disease for such patients and their practitioners, and to select disease progression tutorials that are directed to the specific patient attributes and their corresponding effect on disease progression over time.

Integrated disease information system

A hierarchical biological modelling system and method provides integrated levels of information synthesized from multiple sources. An executable model of a biological system is developed from information and structures based on the multiple sources. The model is balanced to ensure that it matches the information and structures. Once the model is created and balanced it can be used to provide insight into phenomena at the cellular, or subcellular level, as well as phenomena at the patient, organ and system levels. From this information clinical trials can be emulated, biologic targets for drug development can be identified and subcellular phenomena over time can be observed. The model provides an integrated view of a multi-variable biological system.

Growing community of inventors

Newton, MA, United States of America

Kenneth S Kornman